Phase 2 N=79 Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=228 Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast
Intraductal Carcinoma and Lobular Carcinoma in Situ
Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants
N/A N=3 Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Ductal Breast Carcinoma In Situ · HER2/Neu Positive
Primary: Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS)
Phase 2 N=108 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001
Phase 3 N=2,980 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33
Phase 3 N=2,014 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Breast Ductal Carcinoma In Situ
Primary: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival — 95.1; 96.1 percentage of patients event free
N/A N=69 Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Ductal Carcinoma In Situ
Primary: Percent Change in Proliferation as Measured by Ki-67
Phase 2 N=27 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Ductal Breast Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer
Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=133 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
DCIS
Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects
N/A N=322 Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
Ductal Carcinoma in Situ
Primary: Number of Participants Who Chose Active Monitoring (AM). — 28; 18 Participants
Phase 3 N=3,104 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Breast Cancer
Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
N/A N=38,514 Impact of Radiation Therapy on Breast Conservation in DCIS
DCIS
Primary: Association Between Patient Characteristics and Three-Level Cluster of Treatment Intensity for Primary DCIS — 145; 115; 99; 0 Participants — p=<0.05
N/A N=28,291 Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ
Ductal Carcinoma In Situ
Primary: Side Effects (Claim-based Measure), Including Lymphedema, Seroma, Wound Infection, or Pain — 534; 404; 23; 60 Participants — p=<.001
Phase 2 N=11 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
Breast Cancer
Primary: Change in Blood Concentrations — 4.2; -0.03 ng/ml
Phase 2 N=100 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Ductal Breast Carcinoma In Situ · Estrogen Receptor Positive
Primary: Change in Ki-67 Labeling Index — -1.0; -4.8 percent positive cells
Phase 2 N=12 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Carcinoma, Intraductal, Noninfiltrating · DCIS · Ductal Carcinoma In Situ
Primary: Average Change in the Longest Diameter of the Breast MRI Target Lesion — 6; 43 percentage length change
Phase 2 N=500 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
Breast Cancer · Menopausal Symptoms
Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL
Phase 2 N=50 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
Breast Cancer
Primary: Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline — -0.15; -54; -1; -81.5 mg/dl
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Phase 1 N=20 Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 10 milligrams
Phase 2 N=44 Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathologic Complete Response (pCR) — 19 participants
Phase 2 N=54 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
Breast Cancer · Precancerous Condition
Primary: Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy — 1.00; -0.05 µM/mM creatinine
Phase 1 N=15 HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
Breast Cancer
Primary: Rate of Treatment Regimen Completion — 14 Participants
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
N/A N=324 Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
Ductal Breast Cancer
Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…
Phase 2 N=234 Intraoperative Detection of Residual Cancer in Breast Cancer
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
Phase 2 N=110 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 18 percentage of participants
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants